CDKN2A and non-small cell lung carcinoma: Failure to show a significant correlation between anti‐p16 IgG levels and OS of NSCLC suggests that patients with a late stage NSCLC may have impaired immune responses to increased p16‐derived antigens due to chemotherapy or other unknown reasons.